CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, shared the following update related to ELEVIDYS (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with Duchenne muscular dystrophy. Following the safety update on acute liver failure that was issued on March 18, European Union (EU) reference member country authorities requested that the independent data monitoring committee (DMC)

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared drug-delivery device, today announced that Chief Executive Officer Shaun Bagai will present at the LD Micro Invitational XV: New York 2025 conference taking place at the Westin Grand Central Hotel, New York, NY on April 10, 2025. Mr. Bagai will discuss recent corporate m

SAN FRANCISCO--(BUSINESS WIRE)-- #ai--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced that it has been named an Award Winner in the 2025 Edison Awards, for the third year in a row. Viz HCM, the company’s AI software solution designed to detect and triage patients with signs of hypertrophic cardiomyopathy (HCM), was recognized in the Health Medical & Biotech category and Cardiovascular Health Diagnostics and Monitoring subcategory. The Edison A

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10, 2025 at 12:45 p.m. Eastern Time. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company’s website at ww

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that ten posters and presentations across its commercial and development portfolio will be presented at the International Society for Heart and Lung Transplantation (ISHLT) 45th Annual Meeting and Scientific Sessions taking place April 27 through April 30, 2025 in Boston. “The additional data across our portfolio presented at this year

DUBLIN--(BUSINESS WIRE)--The "Transdermal Skin Patches Market by Types, Application, Distribution Channel, Region and Company Analysis 2025-2033" report has been added to ResearchAndMarkets.com's offering. Transdermal Skin Patches Market is expected to reach US$ 10.98 billion in 2033 from US$ 8.05 billion in 2023, with a CAGR of 3.50% from 2025 to 2033. Human immunodeficiency virus (HIV), osteoporosis, migraine, Parkinson's disease, Alzheimer's disease, stroke, cardiac and hormonal diseases, an

TOKYO & MUNICH--(BUSINESS WIRE)--ENHERTU® Approved in the EU as 1st HER2 Directed Therapy for Patients with HR+, HER2 Low or HER2 Ultralow mBC Following at Least 1 Endocrine Therapy

HANOI, Vietnam--(BUSINESS WIRE)--L’impresa IT globale FPT e GE HealthCare hanno annunciato la sigla di un accordo di cooperazione strategica, espandendo la loro alleanza commerciale per portare avanti lo sviluppo e la strategia relativi ai prodotti e creare un Centro di competenza FPT in Vietnam. Questa collaborazione sempre più ampia rispecchia un’evoluzione strategica dall’impegno basato sui progetti a un’alleanza a lungo termine mirata ad accelerare l’attuazione di soluzioni basate sull’IA,

HANOI, Vietnam--(BUSINESS WIRE)--Het internationale IT-bedrijf FPT en GE HealthCare kondigen een strategisch samenwerkingsakkoord aan, waarmee zij hun commerciële alliantie uitbreiden om productstrategie en -ontwikkeling te bevorderen, en om een FPT Competency Center in Vietnam op te richten. Het verdiepen van deze samenwerking getuigt van een strategische verschuiving van op project gebaseerd engagement naar een langetermijnalliantie bedoeld om de toepassing van oplossingen aangestuurd door AI

HANOI, Vietnam--(BUSINESS WIRE)--FPT, empresa global de TI, y GE HealthCare han anunciado un acuerdo de cooperación estratégica, ampliando su alianza comercial para avanzar en la estrategia y el desarrollo de productos, así como para establecer un Centro de Competencia FPT en Vietnam. Esta cada vez más estrecha colaboración refleja un cambio de rumbo estratégico, pasando de un compromiso basado en proyectos puntuales a una alianza a largo plazo orientada a acelerar la implementación de solucion

HANOI, Vietnam--(BUSINESS WIRE)--Der globale IT-Dienstleister FPT und GE HealthCare International (GEHC) haben eine strategische Kooperationsvereinbarung unterzeichnet. Ziel dieser Kooperation ist es, die Produktstrategie und -entwicklung voranzutreiben und ein FPT-Kompetenzzentrum in Vietnam einzurichten. Die Vertiefung der Zusammenarbeit markiert den Übergang von einem projektbasierten Ansatz hin zu einer langfristigen Partnerschaft. Im Rahmen der kommerziellen Allianz wird FPT als Vertriebsp

加州，聖卡羅--(BUSINESS WIRE)--(美國商業資訊)-- 全球性腫瘤研究公司BeiGene, Ltd.（計畫更名為BeOne Medicines Ltd.；中文名：百濟神州。納斯達克代號：ONC；香港交易所代號：06160；上海證券交易所代號：688235）今天宣布停止可能有治療肺癌潛力的TIGIT抗體「ociperlimab」(BGB-A1217) 之臨床開發計畫。 其獨立資料監查委員會 (Independent Data Monitoring Committee) 根據預先排定的無效性分析結果，建議終止進行中的第三期AdvanTIG-302試驗 (NCT04746924)。其總體有效性及安全性資料評估顯示該研究無法達到整體存活期的主要療效指標；沒有觀察到新的安全信號。經過審慎討論，該公司決定終止該試驗。 「我們評估臨床結果，將資源集中於最有希望的臨床差異性候選藥物，並謹慎排除其他可能性不那麼大的候選藥物。我們堅守為全球癌症患者找出並開發更實惠且可普及之創新療法的承諾。」BeiGene實體腫瘤醫療長Mark Lanasa博士表示，「在此感謝研究人員、其患者和支援工作人員

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), een wereldwijd oncologisch bedrijf dat van plan is zijn naam te veranderen in BeOne Medicines Ltd., heeft vandaag de stopzetting aangekondigd van zijn klinische ontwikkelingsprogramma voor ociperlimab (BGB-A1217), een anti-TIGIT-antilichaam, als mogelijke behandeling voor longkanker. Het Independent Data Monitoring Committee adviseerde om de lopende Fase 3 AdvanTIG-302-studie (NCT04746924) te beëindigen

カリフォルニア州、サンカルロス--(BUSINESS WIRE)--（ビジネスワイヤ） -- グローバルながん領域専門の製薬企業であるベイジーン（NASDAQ：ONC、HKEX：06160、SSE：688235）（BeOne Medicines Ltd.へ社名変更予定）は、肺がんの治療薬候補として開発していた抗TIGIT抗体「オシペルリマブ（BGB-A1217）」の臨床開発プログラムを中止することを発表しました。 独立データモニタリング委員会は、計画的無益性解析の結果に基づき、進行中の第3相AdvanTIG-302試験（NCT04746924）の中止を勧告しました。全体的な有効性および安全性のデータ評価により、本試験が主要評価項目である全生存期間を達成する可能性は低いと判断されました。新たな安全性上の懸念は確認されませんでした。慎重な検討の結果、当社は本試験を中止する決断に至りました。 「私たちは、最も有望で臨床的に差別化された候補に資源を集中するため、臨床開発プログラムを評価し、慎重に優先順位の見直しを行っています。私たちの使命は揺らぎません。世界中のがん患者にとって、より手頃で利

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ : ONC ; HKEX : 06160 ; SSE : 688235), une société internationale d'oncologie qui a l'intention de changer de nom pour devenir BeOne Medicines Ltd, a annoncé aujourd'hui l'arrêt de son programme de développement clinique pour l'ociperlimab (BGB-A1217), un anticorps anti-TIGIT, en tant que traitement potentiel du cancer du poumon. Le comité indépendant de contrôle des données a recommandé de mettre fin à l'essai de phase 3 AdvanTIG-302 (N

SAN CARLOS, Kalifornien, USA--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235) – ein globales Onkologieunternehmen, das künftig unter dem Namen BeOne Medicines Ltd. firmieren wird – gab heute die Einstellung seines klinischen Entwicklungsprogramms für Ociperlimab (BGB-A1217) bekannt, einen Anti-TIGIT-Antikörper und potenzielle Behandlungsoption bei Lungenkrebs. Das unabhängige Datenüberwachungskomitee empfahl die vorzeitige Beendigung der laufenden Phase-3-Studie AdvanTIG-

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), azienda globale attiva in ambito oncologico che intende cambiare il proprio nome in BeOne Medicines Ltd., oggi ha annunciato l'interruzione del programma di sviluppo clinico per ociperlimab (BGB-A1217), un anticorpo anti-TIGIT, come potenziale trattamento del carcinoma polmonare. Il Comitato indipendente per il monitoraggio dei dati ha raccomandato la conclusione dello studio clinico di fase 3 AdvanTIG-3

SAN CARLOS, Califórnia--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), empresa internacional de oncologia que pretende mudar seu nome para BeOne Medicines Ltd., anunciou hoje a descontinuação de seu programa de desenvolvimento clínico para ociperlimabe (BGB-A1217), um anticorpo anti-TIGIT, como um possível tratamento para câncer de pulmão. O Comitê Independente de Monitoramento de Dados recomendou a conclusão do ensaio de fase 3 AdvanTIG-302 em curso (NCT04746924) com b

シアトル--(BUSINESS WIRE)--（ビジネスワイヤ） -- シングルセル・シーケンシングのアクセス性とスケーラビリティをリードするパース・バイオサイエンシズは、東京に拠点を置く株式会社スクラムとの契約締結を公表しました。これにより、日本の研究コミュニティにおける同社のプレゼンスが拡大します。この提携により、学術界および産業界の研究者は、パースの革新的なシングルセル・シーケンシング・ソリューションに完全にアクセスできるようになります。 「アジア全域のバイオテクノロジー、製薬、そして学術研究者たちは、スケーラビリティとシンプルさから、急速にパースのシングルセル・シーケンシング・ソリューションであるEvercodeを採用しています」と、パース・バイオサイエンシズの最高経営責任者（CEO）兼共同創設者であるアレックス・ローゼンバーグ博士は述べています。「株式会社スクラムとの提携により、日本の研究者たちがパースの先進的なシングルセル・シーケンシング・ソリューションを容易に活用し、発見を加速できるようになります」 この契約により、スクラムは、パーズのシングルセル・ソリューションの包括

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), empresa mundial de oncología que se propone cambiar su nombre por el de BeOne Medicines Ltd., acaba de anunciar la interrupción de su programa de desarrollo clínico de ociperlimab (BGB-A1217), un anticuerpo anti-TIGIT, como posible tratamiento del cáncer de pulmón. El Comité Independiente de Supervisión de Datos recomendó finalizar el ensayo en curso de fase 3 AdvanTIG-302 (NCT04746924) basándose en sus

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Blackstone Life Sciences and Anthos Therapeutics, Inc., a transformative, clinical-stage biopharmaceutical company developing innovative therapies for the treatment of cardiometabolic diseases, announced today that Novartis has completed its acquisition of Anthos Therapeutics in a transaction valued at up to $3.1 billion. Anthos was founded by Blackstone Life Sciences and Novartis in 2019 with the exclusive global rights from Novartis to develop, manufacture,

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on April 1, 2025, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 228,000 shares of common stock to five new employees under the Company’s 2024 Induce

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today reported financial results for its second quarter fiscal 2025, ended February 28, 2025. Second Quarter 2025 Financial Highlights (as compared to second quarter 2024) Total revenue increased 23% to $22.4 million Software

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, will present at the Jones Healthcare and Technology Innovation Conference on Wednesday, April 9, 2025. A replay of the presentation will be accessible on the Events page under the Ne

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025